nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A Systematic Review and Quality Assessment of Cardiovascular Disease-Specific Health-Related Quality-of-Life Instruments Part I: Instrument Development and Content Validity
|
Li, Xue |
|
|
27 |
8 |
p. 1130-1148 |
artikel |
2 |
Can Generalized Cost-Effectiveness Analysis Leverage Meaningful Use of Novel Value Elements in Pharmacoeconomics to Inform Medicare Drug Price Negotiation?
|
Padula, William V. |
|
|
27 |
8 |
p. 1100-1107 |
artikel |
3 |
Cost-Effectiveness of Axicabtagene Ciloleucel for Adult Patients With Relapsed or Refractory Follicular Lymphoma in the United States
|
Oluwole, Olalekan O. |
|
|
27 |
8 |
p. 1030-1038 |
artikel |
4 |
Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review
|
Thavorn, Kednapa |
|
|
27 |
8 |
p. 1149-1173 |
artikel |
5 |
Editorial Board
|
|
|
|
27 |
8 |
p. v |
artikel |
6 |
EQ-5D-5L Population Norms for China Derived From a National Health Survey
|
Li, Dan-Lin |
|
|
27 |
8 |
p. 1108-1120 |
artikel |
7 |
Estimating the Allocation of the Economic Value Generated by Utilization of All-Oral Direct-Acting Antivirals for Hepatitis C in the United States, 2015 to 2019
|
Garrison Jr., Louis P. |
|
|
27 |
8 |
p. 1021-1029 |
artikel |
8 |
Health Fluctuations in Dementia and its Impact on the Assessment of Health-Related Quality of Life Using the EQ-5D-5L
|
Michalowsky, Bernhard |
|
|
27 |
8 |
p. 1092-1099 |
artikel |
9 |
How Do the Institute for Clinical and Economic Review’s Assessments of Comparative Effectiveness Compare With the German Federal Joint Committee’s Assessments of Added Benefit? A Qualitative Study
|
DiStefano, Michael J. |
|
|
27 |
8 |
p. 1066-1072 |
artikel |
10 |
Illustrating the Financial Consequences of Outcome-Based Payment Models From a Payers Perspective: The Case of Autologous Gene Therapy Atidarsagene Autotemcel (Libmeldy®)
|
Callenbach, Marcelien H.E. |
|
|
27 |
8 |
p. 1046-1057 |
artikel |
11 |
Implementing Multilevel Network Meta-Regression for Time-To-Event Outcomes: A Case Study in Relapsed Refractory Multiple Myeloma
|
Maciel, Dylan |
|
|
27 |
8 |
p. 1012-1020 |
artikel |
12 |
It Takes 2 to Tango. Setting Out the Conditions in Which Performance-Based Risk-Sharing Arrangements Work for Both Parties
|
Towse, Adrian |
|
|
27 |
8 |
p. 1058-1065 |
artikel |
13 |
Navigating Public Policy Responses to a Pandemic: The Balancing Act Between Physical Health, Mental Health, and Household Income
|
Finkelstein, Eric Andrew |
|
|
27 |
8 |
p. 1121-1129 |
artikel |
14 |
Table of Contents
|
|
|
|
27 |
8 |
p. i-iv |
artikel |
15 |
The Inflation Reduction Act: An Opportunity to Accelerate Confidence in Real-World Evidence in the United States
|
Arora, Paul |
|
|
27 |
8 |
p. 999-1002 |
artikel |
16 |
The Long COVID Symptoms and Severity Score: Development, Validation, and Application
|
Ye, Gengchen |
|
|
27 |
8 |
p. 1085-1091 |
artikel |
17 |
Treatment Effect Waning Assumptions: A Review of National Institute of Health and Care Excellence Technology Appraisals
|
Trigg, Laura A. |
|
|
27 |
8 |
p. 1003-1011 |
artikel |
18 |
Utilization, Expenditure, and Treatment Patterns Associated With Calcitonin Gene-Related Peptide Monoclonal Antibodies Reimbursed Subject to a Managed Access Protocol in Ireland
|
Smith, Amelia |
|
|
27 |
8 |
p. 1039-1045 |
artikel |
19 |
Validating Health Economic Models With the Probabilistic Analysis Check dashBOARD
|
Pouwels, Xavier G.L.V. |
|
|
27 |
8 |
p. 1073-1084 |
artikel |